Bharat Biotech sought permission for Covaxin trial for 2 to 18 age group from DGCI

 
Covaxin sought trail for 2-18 yrs

The country's leading pharma company Bharat Biotech has sought permission from the Drug Controller General of India (DCGI to trial the anti-coronavirus Covaxin vaccine as a booster dose in the age group of two to 18 years. According to a report by news agency ANI, the company had applied for it a week ago.

The company has already completed trials of the initial two doses of Covaxin in the age group of two to 18 years. Recently, Bharat Biotech has also received emergency use permission for two doses of the vaccine for children aged six to 12 years.

Read more: Bharat Biotech upgrading facilities as WHO suspends Covaxin supplies

Simultaneously, Bharat Biotech has also sought emergency use permission for two doses of Covaxin for children aged six to 12 years, but the subject matter expert committee (SEC) has asked for more data to be provided.

Bharat Biotech is the first company in the country to apply to conduct a trial for a preventive or booster dose of the vaccine in the age group of two to 18 years. Currently, the Covaxin vaccine is included under the National COVID Immunization Program for two doses in the age group of 15 to 18 years and as an initial and precautionary dose for people above 18 years of age.

Testing on booster dose of intranasal vaccine is also being done

Also, the company's intranasal (nasal vaccine) booster dose is being tested on a heterogeneous group. According to sources, the process of collecting data for the age group above 18 years has been completed.

Read more: Made in India vaccines better than Pfizer and Moderna: SII CEO Poonawalla